|
業務類別
|
Biotechnology |
|
業務概覽
|
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301. |
| 公司地址
| 1841 Page Mill Road, Suite 100, Palo Alto, CA, USA, 94304 |
| 電話號碼
| +1 925 247-4481 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.evommune.com |
| 員工數量
| 48 |
| Dr. Eugene A. Bauer,M.D. |
Director and Chief Medical Officer |
-- |
21/04/2026 |
| Mr. Luis C. Pena |
Director, President and Chief Executive Officer |
美元 588.46K |
21/04/2026 |
| Mr. Gregory S. Moss |
Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer |
美元 515.04K |
21/04/2026 |
| Mr. Kyle Carver, C.P.A.,M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 501.88K |
21/04/2026 |
| Dr. Jeegar Pravinkumar Patel, PhD |
Chief Scientific Officer |
-- |
21/04/2026 |
| Ms. Janice Suzann Drew, M.P.H. |
Chief of Development Operations |
-- |
21/04/2026 |
|
|
| Mr. Arthur S. Kirsch |
Independent Director |
21/04/2026 |
| Dr. Benjamin F. McGraw,III,Pharm.D. |
Chairman of the Board |
21/04/2026 |
| Dr. Eugene A. Bauer,M.D. |
Director and Chief Medical Officer |
21/04/2026 |
| Dr. Robert Hopfner, M.B.A.,PhD |
Independent Director |
21/04/2026 |
| Mr. Luis C. Pena |
Director, President and Chief Executive Officer |
21/04/2026 |
| Dr. Derek DiRocco, PhD |
Independent Director |
21/04/2026 |
| Dr. David Eric Cohen, M.D. |
Independent Director |
21/04/2026 |
| Ms. Felice Weegen Isabel Verduyn-van |
Independent Director |
21/04/2026 |
|
|
|
|
